基于病灶评估预测仑伐替尼治疗放射性碘难治性分化型甲状腺癌的疗效:韩国多中心回顾性研究
该研究纳入57例接受仑伐替尼治疗的放射性碘难治性分化型甲状腺癌患者,通过基于病灶的评估分析临床和影像学参数。中位无进展生存期5.1个月,中位总生存期19.3个月,客观缓解率38%。病灶显著缩小与较短肿瘤倍增时间相关,初始肿瘤倍增时间短的患者更可能对仑伐替尼有反应。
要点
- 基于病灶的评估和肿瘤倍增时间计算有助于识别仑伐替尼潜在应答者
- 病灶显著缩小与肿瘤倍增时间<12个月显著相关(p=0.02)
- 初始肿瘤倍增时间<6个月的患者更可能对仑伐替尼有反应(p=0.03)
核心结论
- 治疗开始时计算肿瘤倍增时间及基于病灶的肿瘤评估可能有助于识别仑伐替尼潜在应答者并预测治疗反应。
研究设计与样本
- 韩国11家转诊医院的多中心回顾性研究,收集2015年6月至2017年12月接受仑伐替尼治疗的67例患者病历。
- 最终分析57例患者,排除未行甲状腺切除术、仅有非靶病灶或治疗时间<1个月者,其中7例(12.2%)为TKI初治。
- 按RECIST 1.1标准连续评估最多96个可测量病灶直至疾病进展,基于历史CT与治疗开始时基线CT的变化计算肿瘤倍增时间。
主要发现
- 中位无进展生存期为5.1个月(95%CI 4.4-9.5),中位总生存期为19.3个月(95%CI 12.4-未达到)。
- 平均缓解持续时间为6.0±4.4个月,客观缓解率为38%。
- 基于病灶评估,31个病灶(32.2%)出现显著肿瘤缩小(完全缓解或部分缓解),与较短肿瘤倍增时间(<12个月)显著相关(p=0.02)。
- 初始肿瘤倍增时间较短(<6个月)且快速进展的患者更可能对仑伐替尼有反应(p=0.03)。
- 平均每日仑伐替尼剂量≥16 mg或治疗前为TKI初治的患者疾病进展风险较低,但未达统计学显著性(每日剂量p=0.07,TKI暴露p=0.09)。
临床怎么用
- 治疗前可通过计算肿瘤倍增时间及基于病灶的评估来预判仑伐替尼的潜在应答者。
局限性
- 本研究为回顾性研究,样本量较小(最终分析57例),结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Lenvatinib, a tyrosine kinase inhibitor (TKI) recently approved for treating radioactive iodine-refractory differentiated thyroid cancer, has been shown to delay disease progression and provide meaningful benefit for overall survival (OS). However, there is no predictive marker for response to lenvatinib before initiating treatment. We comprehensively analyzed clinical and radiological parameters to predict response to lenvatinib using lesion-based assessments. Methods: Medical records were collected from 67 patients treated with lenvatinib in 11 referral hospitals across Korea from June 2015 to December 2017. Up to 96 measurable lesions, defined as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, were evaluated serially until progressive disease (PD) occurred, and tumor doubling time (TDT) was calculated based on changes between historical computed tomography (CT) scans and baseline CT scans performed at treatment initiation. Results: Excluding patients with anaplastic thyroid cancer, no thyroidectomy, nontarget lesions only, or treatment periods of <1 month, 57 patients were analyzed, of whom 7 (12.2%) were TKI-naive. The median progression-free survival was 5.1 months (95% confidence interval [CI], 4.4-9.5), the median OS was 19.3 months (95% CI 12.4-not reached), the mean duration of response was 6.0 ± 4.4 months, and the objective response rate was 38%. In lesion-based assessments, 31 lesions (32.2%) with significant tumor shrinkage (complete remission or partial response) were significantly associated with shorter TDT (<12 months; p = 0.02). Patients with rapidly PD with a shorter initial TDT (<6 months) were more likely to respond to lenvatinib (p = 0.03). Patients exposed to lenvatinib at an average of ≥16 mg per day, or who were TKI-naive before treatment with lenvatinib, had a lower risk of progression; however, the risk reduction did not reach statistical significance (daily dosage p = 0.07, TKI exposure p = 0.09). Conclusions: TDT calculations at the beginning of treatment and lesion-based tumor assessment may help identify potential responders to lenvatinib therapy and predict therapeutic responses.
引用
- Lee EK, Kim SM, Kim BH, et al. Lesion-Based Evaluation Predicts Treatment Response to Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Korean Multicenter Retrospective Study. Thyroid. 2019. PMID: 31482759. doi:10.1089/thy.2019.0022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。